Journal articles on the topic 'Tumors Measurement'
To see the other types of publications on this topic, follow the link: Tumors Measurement.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Tumors Measurement.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Putri, Maizza Nadia, Kusworo Adi, M.Irwan Katili, Sidin Hariyanto, and Dwi Rochmayanti. "COMPARISON MEASUREMENT AND CALCULATION OF BRAIN TUMOR IN MRI MODALITIES UTILISING SPIN-ECHO PULSE SEQUENCE T1-WEIGHTED CONTRAST AND DIGITAL IMAGE PROCESSING APPLICATIONS." Journal of Vocational Health Studies 6, no. 2 (November 1, 2022): 151–57. http://dx.doi.org/10.20473/jvhs.v6.i2.2022.151-157.
Full textAbstract:
Background: Evaluation of brain tumor MRI image results performed by radiologists employing the linear measurement method has several weaknesses and is sensitive to subjectivity. Purpose: To compare the results of measurements and calculations of brain tumors utilizing the linear measurement method on the Siemens 1.5 Tesla MRI modality employing pulse sequence spin echo with T1 contrast weighting compared with the results of measurements and calculations of brain tumors utilizing the active contour segmentation method. Method: An experimental study was conducted on 32 MRI images. Result: The study’s findings indicated that the linear measurement was more significant than the active contour segmentation method (p-value<0,05). The results were obtained by calculating the sensitivity and specificity values of the diagnostic test, which were calculated to be 87.5%. Conclusion: The active contour segmentation method applied to pulse sequence spin-echo T1-weighted contrast can be utilized as an alternative measurement and calculation of brain tumors with a sensitivity and specificity value of 87.5%. Further research suggests developing a Matlab application to compare the results of measurements and calculations of brain tumors on acquiring 3D image magnetic resonance imaging data.
2
Ferrari, L., E. Seregni, A. Martinetti, B. Van Graafeiland, S. Nerini-Molteni, C. Botti, S. Artale, S. Cresta, and E. Bombardieri. "Chromogranin a Measurement in Neuroendocrine Tumors." International Journal of Biological Markers 13, no. 1 (January 1998): 3–9. http://dx.doi.org/10.1177/172460089801300102.
Full textAbstract:
Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.
3
Erasmus, Jeremy J., Gregory W. Gladish, Lyle Broemeling, Bradley S. Sabloff, Mylene T. Truong, Roy S. Herbst, and Reginald F. Munden. "Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response." Journal of Clinical Oncology 21, no. 13 (July 1, 2003): 2574–82. http://dx.doi.org/10.1200/jco.2003.01.144.
Full textAbstract:
Purpose: Response of solid malignancies to therapy is usually determined by serial measurements of tumor size. The purpose of our study was to assess the consistency of measurements performed by readers evaluating lung tumors. Materials and Methods: The study group was composed of 33 patients with lung tumors more than 1.5 cm. Bidimensional (BD) and unidimensional (UD) measurements were performed on computed tomography (CT) scans according to the World Health Organization (WHO) criteria and the Response Evaluation Criteria in Solid Tumors (RECIST), respectively. Measurements were performed independently by five thoracic radiologists using printed film and were repeated after 5 to 7 days. Inter- and intraobserver measurement variations were estimated through statistical modeling. Results: There were 40 tumors with an average size of 1.8 to 8.0 cm (mean, 4.1 cm). Analysis of variance showed a significant difference (P < .05) among readers and among the measured nodules for UD and BD measurements. Interobserver misclassification rates were more than intraobserver misclassification rates using either progressive disease or response criteria. The probability of misclassifying a tumor with the WHO criteria or RECIST was greatest with interobserver measurements when criteria for progression (43% BD, 30% UD) were used and lowest with intraobserver measurements when criteria for response (2.5% BD, 3.0% UD) were used. In addition, interobserver misclassification rates were more than intraobserver misclassification rates for both regular and irregular tumors. Conclusion: Measurements of lung tumor size on CT scans are often inconsistent and can lead to an incorrect interpretation of tumor response. Consistency can be improved if the same reader performs serial measurements for any one patient.
4
Wustefeld-Janssens, Brandan G., Arathi Vinayak, Lindsay A. Parker, and Danielle L. Hollenbeck. "Quantification of Canine Apocrine Gland Anal Sac Adenocarcinoma (AGASACA) Tumor Specimen Shrinkage after Formalin Fixation." Animals 12, no. 15 (July 22, 2022): 1869. http://dx.doi.org/10.3390/ani12151869.
Full textAbstract:
The aim was to prospectively measure the shrinkage of primary apocrine gland anal sac adenocarcinoma (AGASACA) tumors after 24 and 48 h of formalin fixation. Dogs that were diagnosed with AGASACA pre-operatively by aspiration cytology were prospectively enrolled in the study. Tumor extirpation was performed in a closed technique. The tumor and associated tissues were examined on the back table away from the patient and the widest dimension of the tumor was measured using a sterile ruler (Medline®; Northfield, IL, USA). This measurement was recorded in mm (t0). The tissue was placed in 10% buffered formalin and stored at room temperature. Two further measurements were taken after 24 (t24) and 48 (t48) hours of formalin fixation. Once the 48 h measurement was taken, the tissue was submitted for histopathology. The percentage of shrinkage between time points was calculated by using the following equation: (1 − [time b/time a]) × 100. Overall, 23 dogs with 23 tumors were enrolled. The mean percentage of shrinkage after 24 and 48 h of formalin fixation was 4.8% and 7.2%, respectively. The median diameter of the tumors reduced by 1 mm over 48 h and was not significantly different at any time point. These data will aid clinicians in interpreting measurements of AGASACA tumors following formalin fixation and shows that minimal change in tumor size is expected following 48 h.
5
Xu, Xiaohong, Liangping Luo, Jiexin Chen, Jiexin Wang, Honglian Zhou, Mingyi Li, Zhanqiang Jin, et al. "Acoustic Radiation Force Impulse Elastography for Efficacy Evaluation after Hepatocellular Carcinoma Radiofrequency Ablation: A Comparative Study with Contrast-Enhanced Ultrasound." BioMed Research International 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/901642.
Full textAbstract:
Aim. To explore acoustic radiation force impulse (ARFI) elastography in assessing residual tumors of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA).Materials and Methods. There were 83 HCC lesions among 72 patients. All patients were examined with ARFI, contrast enhanced ultrasound (CEUS), and CT or MRI. Tumor brightness on virtual touch tissue imaging (VTI) and shear wave velocity (SWV) were assessed before and approximately one month after RFA.Results. There were 14 residual tumors after RFA. VTI showed that all the tumors were darker after RFA. VTI was not able to distinguish the ablated lesions and the residual tumors. 13 residual tumor lesions were detected by CEUS. All completely ablated nodules had SWV demonstration of x.xx., while with those residual nodules, 6 tumors had x.xx measurement and 8 tumors had measurable SWV. nine lesions with residual tumors occurred in cirrhosis subjects and 5 lesions with residual tumors occurred in fibrosis subjects; there was no residual tumor in the normal liver subjects.Conclusion. VTI technique cannot demonstrate residual tumor post RFA. While SWV measurement of less than x.xx is likely associated with residual tumors, measurement of less than x.xx cannot exclude residual tumors. Liver cirrhosis is associated with decreased chance of a complete ablation.
6
Anderson, Michael, Anna Moshnikova, Donald M. Engelman, Yana K. Reshetnyak, and Oleg A. Andreev. "Probe for the measurement of cell surface pH in vivo and ex vivo." Proceedings of the National Academy of Sciences 113, no. 29 (July 5, 2016): 8177–81. http://dx.doi.org/10.1073/pnas.1608247113.
Full textAbstract:
We have developed a way to measure cell surface pH by positioning a pH-sensitive fluorescent dye, seminaphtharhodafluor (SNARF), conjugated to the pH low insertion peptide (pHLIP). It has been observed that many diseased tissues are acidic and that tumors are especially so. A combination of effects acidifies tumor cell interiors, and cells pump out lactic acid and protons to maintain intracellular pH, acidifying the extracellular space. Overexpression of carbonic anhydrases on cell surfaces further contributes to acidification. Thus, the pH near tumor cell surfaces is expected to be low and to increase with distance from the membrane, so bulk pH measurements will not report surface acidity. Our new surface pH-measurement tool was validated in cancer cells grown in spheroids, in mouse tumor models in vivo, and in excised tumors. We found that the surface pH is sensitive to cell glycolytic activity: the pH decreases in high glucose and increases if glucose is replaced with nonmetabolized deoxyglucose. For highly metastatic cancer cells, the pH measured at the surface was 6.7–6.8, when the surrounding external pH was 7.4. The approach is sensitive enough to detect 0.2–0.3 pH unit changes in vivo in tumors induced by i.p. injection of glucose. The pH at the surfaces of highly metastatic cells within tumors was found to be about 6.1–6.4, whereas in nonmetastatic tumors, it was 6.7–6.9, possibly creating a way to distinguish more aggressive from less aggressive tumors. Other biological roles of surface acidity may be found, now that targeted measurements are possible.
7
Gillies, R. J., Z. Liu, and Z. Bhujwalla. "31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate." American Journal of Physiology-Cell Physiology 267, no. 1 (July 1, 1994): C195—C203. http://dx.doi.org/10.1152/ajpcell.1994.267.1.c195.
Full textAbstract:
The extracellular pH (pHex) of tumors is generally acidic. However, it is only recently that noninvasive magnetic resonance spectroscopic (MRS) measurements have determined that the intracellular pH (pHin) of tumor cells in situ is neutral or slightly alkaline compared with that of normal tissues. Thus cells in tumors maintain larger pH gradients than do cells in nontumor tissues. To date, measurements of pHex in tumors have been made using microelectrodes, which preclude measurement of pHex and pHin within the same preparation. In addition, microelectrodes are invasive and have the potential to alter the measured pH values. The present communication describes simultaneous measurement of pHex and pHin in vitro in bioreactor culture and in vivo using 31P-MRS analyses of 3-aminopropylphosphonate (3-APP) and inorganic phosphate. In vitro results indicate that 3-APP is not toxic and that its resonant frequency is sensitive to pH and not significantly affected by temperature or ionic strength. Bioreactor experiments indicate that this compound is neither internalized nor metabolized by cells. Experiments in vivo indicate that 3-APP can be administered intraperitoneally and that RIF-1 tumors maintain a steady-state pHin of 7.25 and a pHex of 6.66. These data have significance to basic tumor cell physiology and to the design of approaches to cancer chemotherapy and hyperthermic therapy, because both of these modalities exhibit pH sensitivity. It is also likely that these techniques will be applicable to localized MRS of other organ systems in vivo.
8
Moats, Rex A., Sendhil Velan-Mullan, Russell Jacobs, Ignacio Gonzalez-Gomez, David J. Dubowitz, Takashi Taga, Vazgen Khankaldyyan, et al. "Micro-MRI at 11.7 T of a Murine Brain Tumor Model Using Delayed Contrast Enhancement." Molecular Imaging 2, no. 3 (July 1, 2003): 153535002003031. http://dx.doi.org/10.1162/15353500200303112.
Full textAbstract:
In vivo imaging methodologies allow for serial measurement of tumor size, circumventing the need for sacrificing mice at given time points. In orthotopically transplanted murine models of brain tumors, cross-section micro-MRI allows for visualization and measurement of the physically inaccessible tumors. To allow for long resident times of a contrast agent in the tumor, intraperitoneal administration was used as a route of injection for contrast-enhanced micro-MRI, and a simple method for relative tumor volume measurements was examined. A strategy for visualizing the variability of the delayed tumor enhancement was developed. These strategies were applied to monitor the growth of brain tumors xenotransplanted into nude mice and either treated with the antiangiogenic peptide EMD 121974 or an inactive control peptide. Each mouse was used as its own control. Serial imaging was done weekly, beginning at Day 7 after tumor cell implantation and continued for 7 weeks. Images obtained were reconstructed on the MRI instrument. The image files were transferred off line to be postprocessed to assess tumor growth (volume) and variability in enhancement (three-dimensional [3-D] intensity models). In a small study, tumor growth and response to treatment were followed using this methodology and the high-resolution images displayed in 3-D allowed for straightforward qualitative assessment of variable enhancement related to vascular factors and tumor age.
9
Lapa, Constantin, Andreas Buck, Michael Lassmann, Rudolf Werner, and Heribert Hänscheid. "Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC." Nuklearmedizin 56, no. 06 (2017): 219–24. http://dx.doi.org/10.3413/nukmed-0925-17-08.
Full textAbstract:
SummaryAim: To retrospectively analyze the accuracy of absorbed dose estimates from a single measurement of the activity concentrations in tumors and relevant organs one to three days after the administration of 177Lu-DOTA-TATE/TOC assuming tissue specific effective half-lives. Methods: Activity kinetics in 54 kidneys, 30 neuroendocrine tumor lesions, 25 livers, and 27 spleens were deduced from series of planar images in 29 patients. After adaptation of mono- or bi-exponential fit functions to the measured data, it was analyzed for each fit function how precise the time integral can be estimated from fixed tissue-specific half-lives and a single measurement at 24, 48, or 72 h after the administration. Results: For the kidneys, assuming a fixed tissue-specific half-life of 50 h, the deviations of the estimate from the actual integral were median (5 % percentile, 95 % percentile): -3 °% (-15 %>; +16 °%) for measurements after 24 h, +2 %> (-9 %>; +12 %>) for measurements after 48 h, and 0 % (-2 %; +12 %) for measurements after 72 h. The corresponding values for the other tissues, assuming fixed tissue-specific half-lives of 67 h for liver and spleen and 77 h for tumors, were +2 % (-25 %; +20 %) for measurements after 24 h, +2 °% (-16 %>; +17 %>) for measurements after 48 h, and +2 %> (-11 %>; +10 %>) for measurements after 72 h. Conclusions: Especially for the kidneys, which often represent the dose limiting organ, but also for liver, spleen, and neuroendocrine tumors, a meaningful absorbed dose estimate is possible from a single measurement after 2, more preferably 3 days after the administration of 177Lu-DOTA-TATE/-TOC assuming fixed tissue specific effective half-lives.
10
Allakhverdieva, G. F., A. M. Mudunov, and A. F. Batsev. "Use of transoral ultrasonography technique in tongue cancer: Advantages and disadvantages." MD-Onco 2, no. 4 (December 14, 2022): 41–45. http://dx.doi.org/10.17650/2782-3202-2022-2-4-41-45.
Full textAbstract:
Aim. To evaluate advantages and disadvantages of transoral ultrasonography (US) in tongue cancer.Materials and methods. US was performed in 165 patients between the ages of 15 and 85 years with malignant tumors of the mobile tongue (74 (44.9 %) women, 91 (55.1 %) men).Among 165 patients, 144 had primary tongue tumor. The study also included 21 (12.7 %) patients with recurrent tumor which clinically could be represented by a true recurrence (tumor development 6 months after the end of treatment) or by continued growth (tumor development less than 6 months after the end of treatment). The study included patients with tongue tumors Т1 - 50 (30.3 %) patients, Т2 - 78 (47.3 %) patients, Т3 - 16.4 % of patients, Т4 - 6.1 % of patients.Three types of approach to tongue tumor visualization were used: submandibular, transoral, and transbuccal with a standard linear transducer (4-9 MHz) and intraoperative linear transducer (5-14 MHz). In total in 165 patients with tongue tumors, 147 (89.1 %) transoral US, 86 (52.1 %) submandibular US and 25 (15.2 %) transbuccal US examinations were performed.Results. Among 165 patients, agreement between the sizes measured using US and histological examination was observed in 142 (86.1 %) patients taking into account 15 % error.With increasing tumor thickness and, correspondingly, T criterion, increased frequency of agreement between US data and histological data was observed. Thus, for T1 stage frequency of agreement with US data was observed in 61.8 % of cases, for Т2 stage in 81.1 % of cases, for Т3 stage in 93.8 %, and for Т4 stage agreement was observed in 100 % of cases.Frequency of agreement with histological data in evaluation of tongue tumor thickness for transoral approach was significantly higher than for submandibular approach (р = 0.014). Transoral technique was more accurate for measurement of thickness of primary tumors - 80.3 % of results agreed with histological examination, and for recurrences frequency of agreement was only 33.3 %. Submandibular approach for primary tumors showed accurate measurements only in 67.6 % of cases, in recurrent tumors in 58.3 % of cases. Transbuccal approach also showed higher measurement accuracy for tumor thickness in primary patients (70.0 %) compared to recurrent tumors (40.0 %).Conclusion. Use of transoral ultrasonography significantly improves clinical staging of tongue tumors at the preoperative stage.
11
Arbit, E., G. R. DiResta, R. F. Bedford, N. K. Shah, and J. H. Galicich. "Intraoperative Measurement of Cerebral and Tumor Blood Flow with Laser-Doppler Flowmetry." Neurosurgery 24, no. 2 (February 1, 1989): 166–70. http://dx.doi.org/10.1227/00006123-198902000-00003.
Full textAbstract:
Abstract A new technique, laser-Doppler flowmetry, has been used intraoperatively to measure blood flow responses in normal brain tissue and brain tumor to blood pressure and arterial blood gas alterations. We have observed that blood flow is reduced in most cerebral tumors, and that most tumors retain the normal response to changes in arterial blood gas; however, these responses are varied. One group of tumors in our study demonstrated an autoregulatory capacity; a second behaved passively—that is, blood flow changes followed blood pressure—while a third showed no response.
12
Milroy, Christopher M., Kenneth O. Devaney, Alfio Ferlito, and Alessandra Rinaldo. "Role of DNA Measurements of Head and Neck Tumors." Annals of Otology, Rhinology & Laryngology 106, no. 9 (September 1997): 801–4. http://dx.doi.org/10.1177/000348949710600919.
Full textAbstract:
The measurement of DNA ploidy has been used as a tool to try to determine the prognosis of many neoplasms. DNA ploidy can be determined by flow cytometry or image analysis of a tumor. In squamous carcinomas of the head and neck, a poorer prognosis has been associated with nondiploid tumors. Similar results have been obtained from studies of salivary gland neoplasms. The role of DNA ploidy as a provider of independent information has yet to be determined. With rarer head and neck tumors, measurement of tumor ploidy has yet to be established as a valuable adjunct to routine light microscopic study.
13
Schwake, Michael, Sadahiro Kaneko, Eric Suero Morina, and Walter Stummer. "SURG-10. SPECTROSCOPIC MEASUREMENT OF 5-ALA-INDUCED INTRACELLULAR PROTOPORPHYRIN IX IN PEDIATRIC BRAIN TUMORS." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii462—iii463. http://dx.doi.org/10.1093/neuonc/noaa222.807.
Full textAbstract:
Abstract OBJECTIVE 5-ALA guided resection of glioma in adults enables better delineation between tumor and normal brain, allowing improved resection and improved patients’ outcome. Recently, several reports were published regarding 5-ALA for resection of pediatric brain tumors. The aim of the study was to determine the intracellular fluorescence of PPIX in pediatric brain tumors by hyperspectral imaging and to compare it with visually observed intraoperative fluorescence. METHODS 5-ALA was administered orally four hours prior to surgery. During tumor resection the surgeon assessed the fluorescence signal to be strong, weak or absent. Subsequently, fluorescence intensity of samples was measured via spectroscopy. In addition, clinical data, imaging and laboratory data were analyzed. RESULTS Eleven children (1–16 years) were operated. Tumor entities included: three medulloblastomas, two pilocytic astrocytomas (PA), two anaplastic ependymomas and one diffuse astrocytoma, anaplastic astrocytoma, pilomyxoid astrocytoma and anaplastic pleomorphic xanthoastrocytoma. Strong fluorescence was visible in all anaplastic tumors and one PA; one PA demonstrated weak fluorescence. Visible fluorescence was strongly associated with intracellular fluorescence intensity and PPIX concentration (P<0.05). Within all tumors with visible fluorescence the intracellular PPIX concentration was greater than 4 µg/ml. Except for moderate and transient elevation of liver enzymes, no 5-ALA related adverse events were reported. CONCLUSION We demonstrate a strong association between intraoperative observations and spectrometric measurements of PPIX fluorescence in tumor tissue. As in former studies, fluorescence signal was more commonly observed in malignant glial tumors. Further prospective controlled trials should be conducted to investigate the feasibility of 5-ALA guided resection of pediatric brain tumors.
14
YAZAWA, Mitsuhiro, Masaru OKUDA, Asuka SETOGUCHI, Ryohei NISHIMURA, Nobuo SASAKI, Atsuhiko HASEGAWA, WATARI, and Hajime TSUJIMOTO. "Measurement of Telomerase Activity in Dog Tumors." Journal of Veterinary Medical Science 61, no. 10 (1999): 1125–29. http://dx.doi.org/10.1292/jvms.61.1125.
Full text
15
Bagatell, Rochelle, Kieran McHugh, Arlene Naranjo, Collin Van Ryn, Chaim Kirby, Penelope Brock, Karen A. Lyons, et al. "Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study." Journal of Clinical Oncology 34, no. 7 (March 1, 2016): 740–46. http://dx.doi.org/10.1200/jco.2015.63.2042.
Full textAbstract:
Purpose The International Neuroblastoma Response Criteria (INRC) require serial measurements of primary tumors in three dimensions, whereas the Response Evaluation Criteria in Solid Tumors (RECIST) require measurement in one dimension. This study was conducted to identify the preferred method of primary tumor response assessment for use in revised INRC. Patients and Methods Patients younger than 20 years with high-risk neuroblastoma were eligible if they were diagnosed between 2000 and 2012 and if three primary tumor measurements (antero-posterior, width, cranio-caudal) were recorded at least twice before resection. Responses were defined as ≥ 30% reduction in longest dimension as per RECIST, ≥ 50% reduction in volume as per INRC, or ≥ 65% reduction in volume. Results Three-year event-free survival for all patients (N = 229) was 44% and overall survival was 58%. The sensitivity of both volume response measures (ability to detect responses in patients who survived) exceeded the sensitivity of the single dimension measure, but the specificity of all response measures (ability to identify lack of response in patients who later died) was low. In multivariable analyses, none of the response measures studied was predictive of outcome, and none was predictive of the extent of resection. Conclusion None of the methods of primary tumor response assessment was predictive of outcome. Measurement of three dimensions followed by calculation of resultant volume is more complex than measurement of a single dimension. Primary tumor response in children with high-risk neuroblastoma should therefore be evaluated in accordance with RECIST criteria, using the single longest dimension.
16
Patard, J., N. Rioux-Leclercq, K. Bensalah, and P. Fergelot. "Biological significance of serum VEGF measurement in renal cell carcinoma." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 4596. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4596.
Full textAbstract:
4596 Background: VEGF plays an important role in Renal Cell Carcinoma (RCC) tumor angiogenesis and is a relevant molecular target. Our objective was to correlate serum VEGF measurement to clinical, biological and pathological variables in renal tumors. Methods: 206 patients who were operated for a renal tumor at our institution were prospectively assessed for serum VEGF measurement (enzyme-linked immunosorbent assay, R&D systems). Informed consent was obtained in all cases. Symptoms at presentation, pre-operative biology (haemoglobin, WBC count, platelet count, serum creatinin, calcemia, CRP, ASAT, ALAT, gamma-glutamyltransferase (γGT), Alkaline Phosphatases), TNM stage, Fuhrman grade and final pathology (benign vs malignant histology, histologic subtype) were systematically recorded. Qualitative and quantitative variables were compared by using Chi-square (Fischer exact test) and Student t tests, respectively. Results: There were 128 males (62.1%) and 78 females (37.9%). 185 tumors were malignant at histology (89.8%) including 155 tumors with clear cell histology (83.8%). Median serum VEGF level was 361 ng/ml (41–3090). Mean serum VEGF was not significantly different between benign and malignant tumors as well as between clear cell and non clear cell carcinomas (p: 0.4 and 0.8 respectively). Serum VEGF was strongly associated with symptoms, T Stage (p: 0.0001), N Stage (p: 0.004), Fuhrman grade (p: 0.007) and tumor necrosis (p: 0.004) but not with M Stage (p: 0.3). Serum VEGF was also found to be strongly associated with: haemoglobin, CRP, platelet count (p: 0.0001) and Alkaline phosphatases (p: 0.001). A weaker association was found between serum VEGF and γGT, ASAT (p: 0.05) or ALAT (p: 0.09). Finally serum VEGF was associated with cancer specific survival (p: 0.01). Conclusion: Serum VEGF is strongly associated with most usual clinical, biological and pathological prognostic parameters in RCC. Serum VEGF measurement should be further evaluated for prognostic purpose as well as for treatment monitoring. No significant financial relationships to disclose.
17
Gallastegui, Aitor, James Cheung, Teresa Southard, and Kelly R. Hume. "Volumetric and linear measurements of lung tumor burden from non-gated micro-CT imaging correlate with histological analysis in a genetically engineered mouse model of non-small cell lung cancer." Laboratory Animals 52, no. 5 (February 13, 2018): 457–69. http://dx.doi.org/10.1177/0023677218756457.
Full textAbstract:
In vivo micro-computed tomography (CT) imaging allows longitudinal studies of pulmonary neoplasms in genetically engineered mouse models. Respiratory gating increases the accuracy of lung tumor measurements but lengthens anesthesia time in animals that may be at increased risk for complications. We hypothesized that semiautomated, volumetric, and linear tumor measurements performed in micro-CT images from non-gated scans would have correlation with histological findings. Primary lung tumors were induced in eight FVB mice with two transgenes (FVB/N-Tg(tetO-Kras2)12Hev/J; FVB.Cg-Tg(Scgb1a1-rtTA)1Jaw/J). Non-gated micro-CT scans were performed and the lungs were subsequently harvested. In the acquired micro-CT scans, measurements of all identified tumors were determined using the following methods: semiautomated three-dimensional (3D) volume, ellipsoid volume, Response Evaluation Criteria in Solid Tumors (RECIST; sum of largest axial (i.e., transverse) diameter from five tumors), sum of largest axial diameters from all tumors (modified RECIST), and average axial diameter. For histological analysis, all five lung lobes were analyzed and the tumor area was summed from measurements made on five histological sections that were 300 µm apart from each other (covering a total depth of 1200 µm). All micro-CT measurement methods had very strong correlation with histological tumor burden (Pearson’s correlation coefficient, 0.87 ( p = 0.0053) −0.98 ( p < 0.0001)). The only methods found to have different correlations were the semiautomated 3D method and the RECIST method (Williams’ test for dependent overlapping correlations, p = 0.013). Our results suggest quantification of lung tumor burden from non-gated micro-CT imaging will reflect histological differences between mice and can therefore be used for between-group comparisons or when concerns about systemic health of research animals may limit lengthy anesthetic procedures.
18
Plathow, Christian, Christian Fink, Sebastian Ley, Michael Puderbach, Monika Eichinger, Ivan Zuna, Astrid Schmähl, and Hans-Ulrich Kauczor. "Measurement of tumor diameter-dependent mobility of lung tumors by dynamic MRI." Radiotherapy and Oncology 73, no. 3 (December 2004): 349–54. http://dx.doi.org/10.1016/j.radonc.2004.07.017.
Full text
19
McGhee, Eric, Juan Uruena, Alex McGhee, Duane Mitchell, Catherine Flores, and W. Gregory Sawyer. "TMIC-50. 3D QUANTIFICATION OF DYNAMIC CYTOKINE GRADIENTS PRODUCED BY PRIMARY TUMOR MODELS." Neuro-Oncology 21, Supplement_6 (November 2019): vi258—vi259. http://dx.doi.org/10.1093/neuonc/noz175.1084.
Full textAbstract:
Abstract BACKGROUND & SIGNIFICANCE The immune response is a coordinated effort directed by cytokine gradients and concentrations. High sensitivity and spatial resolution are necessary to resolve cytokine gradients in 3-dimensions. This system uses in situ confocal fluorescent microscopy with printed bead-based immunoassays. The combination of 3D printing of the beads and biofabrication of patient derived tumors allows for direct imaging, quantification, and movies of tumor cytokine secretion in response to challenges from immune cells, tumor associated fibroblasts, and chemotherapeutic agents. HYPOTHESIS: Cytokine dynamics can be measured in real-time by balancing concentrations of detection antibodies in solution with stationary immunoassay beads with measured capture and release rates. Favorable balancing of assay kinetics can facilitate measurements of concentrations of cytokines between 50 pg/mL to over 2,000 pg/mL. METHODS In situ confocal fluorescent microscopy identifies position, fluorescence, and type of bead relative to the in vitro tumor. Cytokines including IL2, IL6, IL8, IL11, and IFNg and growth factors such as VEGF and TGFb have been measured for a wide range of solid tumors (brain, sarcoma, and epithelial) under different stresses. RESULTS Dynamic gradients of IL8 were found across multiple tumor models showing local concentrations in excess of 2,000 pg/mL. Production rates were estimated to be over 1 protein per second for each cell, and inclusion of cancer associated support cells showed 10x increases in some cytokines. CD4+ cell production of IL2 was confirmed and quantified and showed strong sensitivity to tumor activity and antigen presentation. Multiplexed beads of CCL2, CCL5, CXCL8, CXCL9, and CXCL10 allow for simultaneous measurement of multiple chemokines. Uncertainties associated with fluorescence measurement and quantification of concentrations will be discussed. CONCLUSIONS This integrated system of 3D assay printing, biofabrication of tumors and immune cell constructs, and in situ confocal microscopy provides the first direct measurements of 3D cytokine gradients in response to tumor stress.
20
Aulia Hanum, Achmad Bayhaqi Nasir Aslam, Yuyun Yueniwati, Diah Prabawati Retnani, and Nanik Setjowati. "Measurement of the peritumoral edema and tumor volume ratio in differentiating malignant primary and metastatic brain tumor." GSC Biological and Pharmaceutical Sciences 13, no. 2 (November 30, 2020): 055–61. http://dx.doi.org/10.30574/gscbps.2020.13.2.0295.
Full textAbstract:
Malignant primary and metastatic brain tumors are group of malignancies radiologically difficult to distinguish between one another. Meanwhile, the treatment regimens between the two entities are very different. The right regimen can maintain patient’s survival. MRI is the modality of choice for diagnosing brain tumors; although, malignant primary brain tumors and solitary metastases appear similar on conventional MRI. The difference in the pathophysiology of peritumoral edema in malignant primary and metastatic brain tumors has the potential for differentiation of the two entities. In malignant primary brain tumors, tumor cell infiltration occurs in the edema area, meaning that the peritumoral edema is narrower than that of the metastases. This study analyzed the ratio of peritumoral edema volume to tumor (EP/T volume ratio) in malignant primary and metastatic brain tumors by means of MRI examination with a cross-sectional design, using MRI data on FLAIR and T1WI sequences with contrast in malignant brain tumor of patients that have been pathologically proven. Then, volume contouring was performed on peritumoral edema (EP) and tumor (T), and comparation was done to obtain the EP/T volume ratio. The ratio of EP/T volume data in both groups was analyzed using the Mann–Whitney test with the SPSS 22 software. The results of statistical analysis revealed that the EP/T volume ratio of the malignant primary brain tumor group was smaller with a median value (max-min) of 1.1 (5.65-0.17) and in the metastatic group, 2.3 (64.03-0.09). There was a significant difference in the EP/T volume ratio between the two groups, which the brain metastatic tumor group have a double ratio of EP/T with a value of p=0.008 (p<0.05).
21
Hayashi, Maho, Nobuko Yoshizawa, Yukio Ueda, Tetsuya Mimura, Etsuko Ohmae, Kenji Yoshimoto, Hiroko Wada, Hatusko Nasu, Hiroyuki Ogura, and Harumi Sakahara. "Effect of Source-Detector Distance on the Measurement of Hemoglobin Using Near-Infrared Spectroscopy in Breast Cancer." Technology in Cancer Research & Treatment 18 (January 1, 2019): 153303381983041. http://dx.doi.org/10.1177/1533033819830411.
Full textAbstract:
We measured total hemoglobin concentrations in breast tumors by near-infrared time-resolved spectroscopy. Muscles interfere with measurement when the probe is close to the chest wall. Since the target area of measurement depends on the distance between the light source and probe detector, we inferred that this issue could be solved by reducing the source-detector distance. The purpose of this study was to examine the effects of the source-detector distance on the measurement of total hemoglobin concentration in the breast. We examined 26 patients with breast tumors. Total hemoglobin concentration was measured in tumors and the contralateral normal breasts at source-detector distances of 20 and 30 mm. The difference in total hemoglobin concentration between each tumor and the contralateral breast was calculated. The normal breast total hemoglobin concentration was significantly smaller for the source-detector distance of 20 mm than for the source-detector distance of 30 mm. Differences in source-detector distance did not significantly affect tumor total hemoglobin. The difference in total hemoglobin concentration between the tumor and the contralateral breast obtained at the source-detector distance of 20 mm was significantly higher than that obtained at the source-detector distance of 30 mm. From these results, we considered that measurement with a source-detector distance of 20 mm is less affected by the chest wall than with a source-detector distance of 30 mm and that the difference in total hemoglobin concentration between the tumor and the contralateral breast at a source-detector distance of 20 mm can better reflect the net total hemoglobin concentrations of the breast tumors. In conclusion, using a probe with a source-detector distance of 20 mm can more accurately evaluate the total hemoglobin concentration in breast tumors.
22
Schwartz, Lawrence H., Michelle S. Ginsberg, Douglas DeCorato, Lawrence N. Rothenberg, Steven Einstein, Peter Kijewski, and David M. Panicek. "Evaluation of Tumor Measurements in Oncology: Use of Film-Based and Electronic Techniques." Journal of Clinical Oncology 18, no. 10 (May 10, 2000): 2179–84. http://dx.doi.org/10.1200/jco.2000.18.10.2179.
Full textAbstract:
PURPOSE: To evaluate the variability in bidimensional computed tomography (CT) measurements obtained of actual tumors and of tumor phantoms by use of three measurement techniques: hand-held calipers on film, electronic calipers on a workstation, and an autocontour technique on a workstation. MATERIALS AND METHODS: Three radiologists measured 45 actual tumors (in the lung, liver, and lymph nodes) on CT images, using each of the three techniques. Bidimensional measurements were recorded, and their cross-products calculated. The coefficient of variation was calculated to assess interobserver variability. CT images of 48 phantoms were measured by three radiologists with each of the techniques. In addition to the coefficient of variation, the differences between the cross-product measurements of tumor phantoms themselves and the measurements obtained with each of the techniques were calculated. RESULTS: The differences between the coefficients of variation were statistically significantly different for the autocontour technique, compared with the other techniques, both for actual tumors and for tumor phantoms. There was no statistically significant difference in the coefficient of variation between measurements obtained with hand-held calipers and electronic calipers. The cross-products for tumor phantoms were 12% less than the actual cross-product when calipers on film were used, 11% less using electronic calipers, and 1% greater using the autocontour technique. CONCLUSION: Tumor size is obtained more accurately and consistently between readers using an automated autocontour technique than between those using hand-held or electronic calipers. This finding has substantial implications for monitoring tumor therapy in an individual patient, as well as for evaluating the effectiveness of new therapies under development.
23
Chen, Haisong, Zengjie Wu, Wenjian Xu, Jing Pang, Meng Jia, Cheng Dong, and Xiaoli Li. "Evaluating the Scope of Malignant Bone Tumor Using ADC Measurement on ADC Map." Technology in Cancer Research & Treatment 18 (January 1, 2019): 153303381985326. http://dx.doi.org/10.1177/1533033819853267.
Full textAbstract:
Background: It is very important for surgeons to know the accurate borders of malignant bone tumors before they can precisely resect the tumors. The objective of the study is to investigate the usefulness of apparent diffusion coefficient value for estimating the extent of malignant bone tumor. Methods: VX2 tumor fragments were implanted into the tibiae of 30 rabbits. After 4 weeks, magnetic resonance plain scans were performed and then tumor specimens were cut into sagittal sections and partitioned into histology slices for dot-to-dot comparisons with microscopic findings. The sizes of the tumors measured separately on specimen, conventional magnetic resonance imaging sequences, and diffusion-weighted imaging (by measuring apparent diffusion coefficient value on apparent diffusion coefficient mapping) were compared statistically with each other. Results: The mean tumor sizes measured on specimen and apparent diffusion coefficient mapping (by calculating apparent diffusion coefficient value) were 5.20 ± 0.89 cm and 5.31 ± 0.87 cm, respectively; there was no significant difference between the 2 ( P > .05). The tumor sizes measured on T1WI, T2WI, T2WI with fat suppression were 4.82 ± 0.87 cm, 5.58 ± 0.87 cm, 5.63 ± 0.85 cm, respectively, and these values were significantly different from that measured on specimen (5.20 ± 0.89 cm, P < .05). Conclusion: The extent of the VX2 malignant bone tumor can be estimated accurately by measurement of apparent diffusion coefficient value.
24
Pang, Angela, Mariana Carbini, Elizabeth Demicco, and Robert G. Maki. "Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate?" Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e22522-e22522. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e22522.
Full textAbstract:
e22522 Background: In the AJCC version 7 TNMG staging of soft tissue sarcomas (STS), the longest dimension (1D) of the primary tumor at pathology analysis is the gold standard for tumor size (T) staging. However, measurements may differ between scans and actual tissue measurement, due to tissue elasticity, deformation, and/or formalin fixation. Thus, tumor size may change compared to preoperative imaging. Should STS T stage be defined by imaging or by direct tumor measurement? We examined the variability of the measurements between radiology and pathology data, examining 1D, cross sectional area (2D), and tumor volume (3D) to assign a T stage. Methods: We reviewed all patients (pts) with extremity STS who had surgery at Mt Sinai Hospital New York (2010-2015). MRI or CT and resected gross tumor measurements were available for 79 pts. After eliminating 10 samples with grossly irregular shapes and 11 samples with incomplete data, 58 tumors had complete 3D measurements. We calculated Pearson correlation coefficients for paired variables (radiology vs pathology size in 1D, 2D and 3D). Results: Imaging measures correlated well with direct tumor measurements. Pearson correlation coefficients for 1D, 2D and 3D measurements were 0.93, 0.72 and 0.78, respectively (all p < 0.01). The SEM (radiology/pathology size) = 0.13, i.e. 13% for 1D measurements. Thus, T stage could be incorrectly assigned in up to 13% of samples near 5 cm in size; this proportion decreases the further the tumor is from the 5 cm cutoff. Conclusions: As shown previously in the rationale for RECIST, 1D measures provide the smallest variance between radiology and pathology. The situation is made more complex in AJCC version 8, with four T categories. It remains unclear how to stage the 10-15% of primary STS with irregular shapes. These data support the use of nomograms for risk assessment rather than using bins created by the AJCC tumor staging system. 3D tumor volumes, if used at all, may play a greater role when assessing therapy responses or contending with tumors of irregular shape, rather than for routine STS staging.
25
Feldman, J. M. "Urinary serotonin in the diagnosis of carcinoid tumors." Clinical Chemistry 32, no. 5 (May 1, 1986): 840–44. http://dx.doi.org/10.1093/clinchem/32.5.840.
Full textAbstract:
Abstract To determine whether measurement of serotonin in urine would give useful complementary information to the usual measurement of 5-hydroxyindoleacetic acid (5-HIAA) in urine and platelet serotonin in platelets, I measured these analytes in 75 consecutive patients with carcinoid tumors, and found that 75% had above-normal urinary 5-HIAA excretion, 64% had above-normal serotonin excretion, and 64% had above-normal platelet serotonin concentration. Six patients had increased urinary serotonin, but 5-HIAA excretion and platelet serotonin concentration were normal. Only two of a further 50 patients with solid noncarcinoid tumors--and none of 55 patients with flushing or diarrhea, who did not prove to have a carcinoid tumor--had increased urinary serotonin. Ingestion of four bananas (a food rich in serotonin) increased urinary 5-HIAA but not urinary serotonin excretion of seven normal subjects. Evidently, measurement of urinary serotonin excretion is helpful in the evaluation of patients with suspected carcinoid tumors.
26
Voicu, Ioan Paul, Antonio Napolitano, Alessia Carboni, Massimo Caulo, Andrea Carai, Maria Vinci, Evelina Miele, et al. "IMG-16. WHOLE TUMOR DIFFUSION KURTOSIS IMAGING ANALYSIS FOR DISCRIMINATING PEDIATRIC POSTERIOR FOSSA TUMORS: ACCURACY AND REPEATABILITY." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii358. http://dx.doi.org/10.1093/neuonc/noaa222.351.
Full textAbstract:
Abstract PURPOSE Diffusion kurtosis imaging (DKI) has not yet been tested for pediatric brain tumors. Estimating diffusion values from whole-tumor based (VOI) segmentations may improve diffusion measurement repeatability compared to conventional region-of-interest (ROI) approaches. Our purpose was to compare repeatability between ROI and VOI DKI-derived diffusion measurements and to assess VOI-based DKI accuracy in discriminating among pediatric posterior fossa tumors. MATERIALS AND METHODS We retrospectively analyzed 34 children (19 M, 15F, mean age 7.48 years) with posterior fossa tumors who underwent preoperative 3T MRI including DKI. For each patient, two neuroradiologists independently segmented the whole solid tumor (VOI), the area of maximum tumor diameter and a smallROI.Inter-observer variability was assessed with coefficient of variation (COV) and Bland-Altman plots. VOI-based DKI metrics accuracy in discriminating among tumor histology and for tumor grading were assessed with MANOVA and ROC analyses respectively. Correlation between grading accuracy and inter-observer variability was assessed with Spearman’s rho. RESULTS Tumor histology included medulloblastoma (15), pilocytic astrocytoma (14) and ependymoma (5). VOI-based measurements presented lower variability than ROI-based measurements across all DKI metrics. DKI-derived metrics could accurately discriminate between tumor subtypes (Pillai’s trace: p<0.001) and were accurate for tumor grading (AUCs of 0.919, 0.986, 0.996, 0.842 and 0.926 for RK, MK, AK, FA and MD respectively). VOI-based COV was significantly correlated to AUC values (R=-0.900, p<0.037). CONCLUSIONS DKI-derived metrics are useful for pediatric posterior fossa tumor discrimination and grading. VOI-based diffusion measurements present improved repeatability compared to ROI-based measurements and are significantly correlated to diagnostic accuracy.
27
Gomes, Tiago Augusto, Elizabeth Aparecida Campos, Adriana Yoshida, Luís Otavio Sarian, Liliana Aparecida Lucci de Angelo Andrade, and Sophie Françoise Derchain. "Preoperative Differentiation of Benign and Malignant Non-epithelial Ovarian Tumors: Clinical Features and Tumor Markers." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 42, no. 09 (September 2020): 555–61. http://dx.doi.org/10.1055/s-0040-1712993.
Full textAbstract:
Abstract Objective To evaluate the role of clinical features and preoperative measurement of cancer antigen 125 (CA125), human epididymis protein (HE4), and carcinoembryonic antigen (CEA) serum levels in women with benign and malignant non-epithelial ovarian tumors. Methods One hundred and nineteen consecutive women with germ cell, sex cord-stromal, and ovarian leiomyomas were included in this study. The preoperative levels of biomarkers were measured, and then surgery and histopathological analysis were performed. Information about the treatment and disease recurrence were obtained from the medical files of patients. Results Our sample included 71 women with germ cell tumors (64 benign and 7 malignant), 46 with sex cord-stromal tumors (32 benign and 14 malignant), and 2 with ovarian leiomyomas. Among benign germ cell tumors, 63 were mature teratomas, and, among malignant, four were immature teratomas. The most common tumors in the sex cord-stromal group were fibromas (benign) and granulosa cell tumor (malignant). The biomarker serum levels were not different among benign and malignant non-epithelial ovarian tumors. Fertility-sparing surgeries were performed in 5 (71.4%) women with malignant germ cell tumor. Eleven (78.6%) patients with malignant sex cord-stromal tumors were treated with fertility-sparing surgeries. Five women (71.4%) with germ cell tumors and only 1 (7.1%) with sex cord-stromal tumor were treated with chemotherapy. One woman with germ cell tumor recurred and died of the disease and one woman with sex cord-stromal tumor recurred. Conclusion Non-epithelial ovarian tumors were benign in the majority of cases, and the malignant cases were diagnosed at initial stages with good prognosis. The measurements of CA125, HE4, and CEA serum levels were not useful in the preoperative diagnosis of these tumors.
28
Kounelakis, Michalis G., Ekaterini S. Bei, Michalis E. Zervakis, Georgios C. Giakos, Lin Zhang, Chaya Narayan, and Dimitrios Kafetzopoulos. "Measurement Methodologies for Assessing the Glycolysis Effect in the Discrimination and Therapy of Brain Gliomas." International Journal of Monitoring and Surveillance Technologies Research 1, no. 1 (January 2013): 34–55. http://dx.doi.org/10.4018/ijmstr.2013010103.
Full textAbstract:
Primary brain tumors refer to those developing from the various types of cells that compose the brain. Gliomas represent about 50% of all primary brain tumors and include a variety of different histological tumor types and malignancy grades. The World Health Organization (WHO) classifies gliomas into four histological types and four grades. The goal of molecular classification using advanced pattern recognition tools is to identify subgroups of tumors with distinct biological and clinical features and initiate the challenge of classifying complex gliomas of similar histology and malignancy status into distinct categories. The aim of this paper is to i) present the measurement procedures and analysis methodologies, ii) summarize the currently available knowledge related to the utilization of ’omics’ measurements in the discrimination of brain gliomas, and iii) provide a scientific basis for future medical practice in the discrimination and treatment of brain gliomas based specifically on the metabolic process of glycolysis. In particular, the paper explores the idea of the glycolysis pathway as a critical concept for the development of therapeutic strategies for brain gliomas.
29
Acar, Nihat, Ahmet Karakasli, Ahmet Karaarslan, Nermin NG Mas, and Onur Hapa. "The reliability of Cavalier’s principle of stereological method in determining volumes of enchondromas using the computerized tomography tools." Journal of Orthopaedic Surgery 25, no. 1 (January 1, 2017): 230949901668450. http://dx.doi.org/10.1177/2309499016684503.
Full textAbstract:
Introduction: Volumetric measurements of benign tumors enable surgeons to trace volume changes during follow-up periods. For a volumetric measurement technique to be applicable, it should be easy, rapid, and inexpensive and should carry a high interobserver reliability. We aimed to assess the interobserver reliability of a volumetric measurement technique using the Cavalier’s principle of stereological methods. Materials and methods: The computerized tomography (CT) of 15 patients with a histopathologically confirmed diagnosis of enchondroma with variant tumor sizes and localizations was retrospectively reviewed for interobserver reliability evaluation of the volumetric stereological measurement with the Cavalier’s principle, V = t × [((SU) × d) /SL]2 × Σ P. Results: The volumes of the 15 tumors collected by the observers are demonstrated in Table 1. There was no statistical significance between the first and second observers ( p = 0.000 and intraclass correlation coefficient = 0.970) and between the first and third observers ( p = 0.000 and intraclass correlation coefficient = 0.981). No statistical significance was detected between the second and third observers ( p = 0.000 and intraclass correlation coefficient = 0.976). Conclusion: The Cavalier’s principle with the stereological technique using the CT scans is an easy, rapid, and inexpensive technique in volumetric evaluation of enchondromas with a trustable interobserver reliability.
30
IZUNAGA, Hiroshi, Yoshihisa HIROTA, Mutsumasa TAKAHASHI, Isao FUWA, Takafumi KODAMA, and Yasuhiko MATSUKADO. "Regional cerebral blood flow measurement in brain tumors." RADIOISOTOPES 35, no. 10 (1986): 528–34. http://dx.doi.org/10.3769/radioisotopes.35.10_528.
Full text
31
Brown, Edward B., Yves Boucher, Selim Nasser, and Rakesh K. Jain. "Measurement of macromolecular diffusion coefficients in human tumors." Microvascular Research 67, no. 3 (May 2004): 231–36. http://dx.doi.org/10.1016/j.mvr.2004.02.001.
Full text
32
Lyubimova, N. V., T. K. Churikova, Yu S. Timofeev, T. Yu Kharitidy, and N. E. Kushlinskii. "Analytical aspects of gastrin measurement in neuroendocrine tumors." Almanac of Clinical Medicine 46, no. 3 (August 3, 2018): 264–69. http://dx.doi.org/10.18786/2072-0505-2018-46-3-264-269.
Full textAbstract:
Rationale:Biochemical diagnostics of neuroendocrine tumors (NETs) is based on the analysis of universal and specific markers, according to the tumor type and clinical manifestations of the disease. Measurement of gastrin levels in the serum of NETs patients is important in the diagnosis of the functioning pancreatic, gastric and duodenal NETs.Aim:To perform a comparative analysis of the results of gastrin measurement as a biochemical marker of NETs using different test-systems.Materials and methods: Serum gastrin was measured in the serum of 30 NET patients and 18 normal controls by immunochemiluminescent (Immulite 2000 Gastrin, “Siemens”) and ELISA (Gastrin-17 ELISA, “Biohit”) assays.Results:The analysis of the results of gastrin measurement by immunochemiluminescent and ELISA methods showed significant variability of its levels, reaching 2016 and 1988 pmol/l, respectively. Comparable analytical sensitivity of the two test systems was confirmed by similar increases (over 30- to 40-fold) of the median levels of the hormone in the serum of patients with gastric NETs, compared to healthy controls. The analysis of diagnostic efficacy accounting for their respective cut-offs demonstrated higher sensitivity (95.4%) of the Immulite 2000 Gastrin test-system, which measures total gastrin, than that of the ELISA method (80.0%), specific to gastrin-17.Conclusion:The analysis shows high efficacy of immonochemiluminescent method of measurement of total gastrin as a biochemical marker of NETs.
33
Oxnard, Geoffrey R., Binsheng Zhao, Camelia S. Sima, Michelle S. Ginsberg, Leonard P. James, Robert A. Lefkowitz, Pingzhen Guo, Mark G. Kris, Lawrence H. Schwartz, and Gregory J. Riely. "Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes." Journal of Clinical Oncology 29, no. 23 (August 10, 2011): 3114–19. http://dx.doi.org/10.1200/jco.2010.33.7071.
Full textAbstract:
Purpose We use changes in tumor measurements to assess response and progression, both in routine care and as the primary objective of clinical trials. However, the variability of computed tomography (CT) –based tumor measurement has not been comprehensively evaluated. In this study, we assess the variability of lung tumor measurement using repeat CT scans performed within 15 minutes of each other and discuss the implications of this variability in a clinical context. Patients and Methods Patients with non–small-cell lung cancer and a target lung lesion ≥ 1 cm consented to undergo two CT scans within a period of minutes. Three experienced radiologists measured the diameter of the target lesion on the two scans in a side-by-side fashion, and differences were compared. Results Fifty-seven percent of changes exceeded 1 mm in magnitude, and 33% of changes exceeded 2 mm. Median increase and decrease in tumor measurements were +4.3% and −4.2%, respectively, and ranged from 23% shrinkage to 31% growth. Measurement changes were within ± 10% for 84% of measurements, whereas 3% met criteria for progression according to Response Evaluation Criteria in Solid Tumors (RECIST; ≥ 20% increase). Smaller lesions had greater variability of percent measurement change (P = .005). Conclusion Apparent changes in tumor diameter exceeding 1 to 2 mm are common on immediate reimaging. Increases and decreases less than 10% can be a result of the inherent variability of reimaging. Caution should be exercised in interpreting the significance of small changes in lesion size in the care of individual patients and in the interpretation of clinical trial results.
34
Chan, Si-Wa, Wei-Hsuan Hu, Yen-Chieh Ouyang, Hsien-Chi Su, Chin-Yao Lin, Yung-Chieh Chang, Chia-Chun Hsu, Kuan-Wen Chen, Chia-Chen Liu, and Sou-Hsin Chien. "Quantitative Measurement of Breast Tumors Using Intravoxel Incoherent Motion (IVIM) MR Images." Journal of Personalized Medicine 11, no. 7 (July 13, 2021): 656. http://dx.doi.org/10.3390/jpm11070656.
Full textAbstract:
Breast magnetic resonance imaging (MRI) is currently a widely used clinical examination tool. Recently, MR diffusion-related technologies, such as intravoxel incoherent motion diffusion weighted imaging (IVIM-DWI), have been extensively studied by breast cancer researchers and gradually adopted in clinical practice. In this study, we explored automatic tumor detection by IVIM-DWI. We considered the acquired IVIM-DWI data as a hyperspectral image cube and used a well-known hyperspectral subpixel target detection technique: constrained energy minimization (CEM). Two extended CEM methods—kernel CEM (K-CEM) and iterative CEM (I-CEM)—were employed to detect breast tumors. The K-means and fuzzy C-means clustering algorithms were also evaluated. The quantitative measurement results were compared to dynamic contrast-enhanced T1-MR imaging as ground truth. All four methods were successful in detecting tumors for all the patients studied. The clustering methods were found to be faster, but the CEM methods demonstrated better performance according to both the Dice and Jaccard metrics. These unsupervised tumor detection methods have the advantage of potentially eliminating operator variability. The quantitative results can be measured by using ADC, signal attenuation slope, D*, D, and PF parameters to classify tumors of mass, non-mass, cyst, and fibroadenoma types.
35
Zhang, Janie Yue, Michael Cecchini, Shruti S. Desai, and Kurt A. Schalper. "Clinical significance and biomarker potential of MGMT protein measurement in colorectal cancer." Journal of Clinical Oncology 40, no. 4_suppl (February 1, 2022): 136. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.136.
Full textAbstract:
136 Background: O6-methylguanine DNA methyltransferase (MGMT) is the principal repair mechanism of DNA damage created by alkylating agents. Approximately 40% of colorectal cancers (CRC) exhibit MGMT promoter hypermethylation, expected to result in gene silencing. The role of MGMT as a biomarker is poorly understood, and quantitative measurement of MGMT protein has not been performed in CRC. We hypothesized that altered tumor MGMT would affect DNA damage response, modulate adaptive anti-tumor immune responses, and influence survival in CRC. Methods: We used multiplexed quantitative immunofluorescence (QIF) to study 4 clinically annotated retrospective patient cohorts treated from 2000 to 2017 at Yale, consisting of 400 formalin-fixed paraffin-embedded CRC cases represented in tissue microarray format. These included paired tumors and adjacent non-tumor colonic mucosa (n = 112 pairs in Cohort 1), paired primary CRC and lymph node metastases (n = 31 pairs in Cohort 2), and 2 cohorts with primary stage I-IV tumors (n = 250 in Cohort 3; n = 150 in Cohort 4). We established a QIF panel for simultaneous, localized measurement of DAPI (all cells), cytokeratin (CK; tumor epithelial cells), MGMT, γH2AX (DNA damage response), and CD8. The measurement of fluorescent signals in CK-positive tumor cells or CK-negative stromal cells was achieved using co-localization strategies and the AQUA QIF platform. Results: We identified lower MGMT protein levels in CRC cells than in non-tumor colonic epithelium (p < 0.0001), and in lymph node metastases compared to paired primary CRC tumors (p = 0.0411). Using the visual detection threshold, tumor selective MGMT protein downregulation was identified in 20% of cases in Cohorts 3 and 4. Microsatellite instability-high (MSI-H) cases showed decreased tumoral MGMT protein compared to microsatellite stable (MSS) cases (p = 0.002). In Cohorts 3 and 4, low tumoral MGMT was consistently associated with increased CD8+ tumor infiltrating lymphocytes (p = 0.0472; p = 0.0002). The association between MGMT and γH2AX was inconsistent. The association between MGMT and CD8 was significant only in MSS cases (p = 0.0001) but not in MSI-H cases (p = 0.0979), supporting that the effect is not driven by MSI-H status. Tumor-selective MGMT downregulation evidenced by a low tumor-to-stroma ratio was associated with improved progression-free survival and overall survival in both Cohorts 3 and 4, but statistical significance was only seen in Cohort 3. Conclusions: MGMT protein downregulation occurs in 20% of CRCs and is associated with increased adaptive anti-tumor immune responses, mismatch repair (MMR) deficiency and better prognosis. MGMT deficiency may alter DNA repair in tumor cells and mediate the accumulation of antigenic mutations or neopeptides, independent from MMR status. Our results support a biomarker role of MGMT protein and suggest a role for immunotherapy combinations in MGMT deficient tumors.
36
Tanaka, Yuichiro, Kazuhiro Hongo, Tsuyoshi Tada, and Shigeaki Kobayashi. "What Is the Best Method for Reporting Tumor Diameter in Vestibular Schwannoma?" Neurosurgery 53, no. 3 (September 1, 2003): 634–38. http://dx.doi.org/10.1227/01.neu.0000080062.61335.a5.
Full textAbstract:
Abstract OBJECTIVE Various methods have been used to report the tumor diameter of vestibular schwannomas. To clarify the most appropriate method to represent the tumor volume, tumor diameters according to various measuring methods were statistically compared with the actual tumor volume. METHODS Tumor volume was measured by three-dimensional constructive interference in steady state images in 52 unselected vestibular schwannomas. Pearson's correlation coefficient was obtained between the tumor volume and various tumor diameters, such as diameter parallel to the petrous edge (a); a pons-to-petrous diameter (b); √ab, a maximum diameter of the portion in the cerebellopontine angle cistern (max CPA); a maximum diameter of the whole tumor (Max); and a diameter through an axis of the internal auditory canal (Axis). The tumors were divided into three groups on the basis of tumor volume, as follows: Group I (small, &3x003C;0.5 cm3), Group II (medium, 0.5–2 cm3), and Group III (large, >2 cm3). RESULTS Max and Axis correlated best with the tumor volume in Group I and correlated least with the tumor volume in Group II. Any of these measurements was acceptable in Group III tumors. The max CPA consistently revealed good correlation with the tumor volume in all three tumor groups. CONCLUSION The max CPA measurement is the simplest and most appropriate way to represent the tumor volume in unselected tumors. Max or Axis is better only when small tumors (<0.5 cm3 in volume) are being assessed—that is, those with a max CPA of less than 1 cm.
37
Jost, Sarah C., Lynne Collins, Sarah Travers, David Piwnica-Worms, and Joel R. Garbow. "Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy." Molecular Imaging 8, no. 5 (September 1, 2009): 7290.2009.00023. http://dx.doi.org/10.2310/7290.2009.00023.
Full textAbstract:
Small-animal tumor models are essential for developing translational therapeutic strategies in oncology research, with imaging having an increasingly important role. Magnetic resonance imaging (MRI) offers tumor localization, volumetric measurement, and the potential for advanced physiologic imaging but is less well suited to high-throughput studies and has limited capacity to assess early tumor growth. Bioluminescence imaging (BLI) identifies tumors early, monitors tumor growth, and efficiently measures response to therapeutic intervention. Generally, BLI signals have been found to correlate well with magnetic resonance measurements of tumor volume. However, in our studies of small-animal models of malignant brain tumors, we have observed specific instances in which BLI data do not correlate with corresponding MRIs. These observations led us to hypothesize that use of BLI and MRI together, rather than in isolation, would allow more effective and efficient measures of tumor growth in preclinical studies. Herein we describe combining BLI and MRI studies to characterize tumor growth in a mouse model of glioblastoma. The results led us to suggest a cost-effective, multimodality strategy for selecting cohorts of animals with similar tumor growth patterns that improves the accuracy of longitudinal in vivo measurements of tumor growth and treatment response in preclinical therapeutic studies.
38
Frenette, Aaron, Joshua Morrell, Kirk Bjella, Edward Fogarty, James Beal, and Vijay Chaudhary. "Do Diametric Measurements Provide Sufficient and Reliable Tumor Assessment? An Evaluation of Diametric, Areametric, and Volumetric Variability of Lung Lesion Measurements on Computerized Tomography Scans." Journal of Oncology 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/632943.
Full textAbstract:
Diametric analysis is the standard approach utilized for tumor measurement on medical imaging. However, the availability of newer more sophisticated techniques may prove advantageous. An evaluation of diameter, area, and volume was performed on 64 different lung lesions by three trained users. These calculations were obtained using a free DICOM viewer and standardized measuring procedures. Measurement variability was then studied using relative standard deviation (RSD) and intraclass correlation. Volumetric measurements were shown to be more precise than diametric. With minimal RSD and variance between different users, volumetric analysis was demonstrated as a reliable measurement technique. Additionally, the diameters were used to calculate an estimated area and volume; thereafter the estimated area and volume were compared against the actual measured values. The results in this study showed independence of the estimated and actual values. Estimated area deviated an average of 43.5% from the actual measured, and volume deviated 88.03%. The range of this variance was widely scattered and without trend. These results suggest that diametric measurements cannot be reliably correlated to actual tumor size. Access to appropriate software capable of producing volume measurements has improved drastically and shows great potential in the clinical assessment of tumors. Its applicability merits further consideration.
39
Ilias, Ioannis, and Karel Pacak. "Developments in Digestive Tract Neuroendocrine Tumors and Pheochromocytomas/Paragangliomas—A Narrative Review." US Endocrinology 07, no. 01 (2011): 59. http://dx.doi.org/10.17925/use.2011.07.01.59.
Full textAbstract:
Digestive neuroendocrine tumors (carcinoids) derive from serotonin-producing enterochromaffin cells. Biochemical screening (and follow-up) is performed with measurements of 5-hydroxyindoloacetic acid in urine. Other markers are also useful. Most digestive neuroendocrine tumors are better localized with functional imaging, i.e. nuclear medicine, compared with other modalities. The treatment of choice is surgical; non-resectable tumors are treated with somatostatin analogs (unlabelled and for more advanced disease radiolabelled) or chemotherapy. Most pheochromocytomas/paragangliomas are sporadic, however, and genetically caused tumors are much more common than previously thought. Biochemical proof of disease is best carried out with measurement of plasma metadrenaline. Imaging with computed tomography or magnetic resonance imaging (MRI) should be followed by functional imaging. Chromaffin tumor-specific methods are preferred.18F-fluoro-deoxyglucose positron emission tomography (18F-DOPA PET) should be used in patients with succinate-dehydrogenase-B-related metastatic pheochromocytoma/paraganglioma.18F-DOPA PET may become a modality of choice for the localization of head and neck paragangliomas. If possible, treatment is surgical. For non-operable disease, other options are available and new drugs are under investigation or in clinical trials.
40
Duong, Duc H., Robert C. Rostomily, David R. Haynor, G. Evren Keles, and Mitchel S. Berger. "Measurement of tumor resection volumes from computerized images." Journal of Neurosurgery 77, no. 1 (July 1992): 151–54. http://dx.doi.org/10.3171/jns.1992.77.1.0151.
Full textAbstract:
✓ The authors describe a method for quantitation of the area and volume of the resection cavity in patients who have undergone surgery for brain tumors. Using a slide scanner and Image 1.27, a public domain program for the Apple Macintosh II computer, computerized tomography scans and magnetic resonance images can be digitized and analyzed for a particular region of interest, such as the area and volume of tumor on preoperative and postresection scans. Phantom scans were used to analyze the accuracy of the program and the program users. User error was estimated at 2%, program error was 4.5%. This methodology is proposed as a means of retrospectively calculating the extent of tumor resection.
41
de Kok, Jacques B., Theo J. M. Ruers, Goos N. P. van Muijen, Adrie van Bokhoven, Hans L. Willems, and Dorine W. Swinkels. "Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in Tumors and Healthy Tissues." Clinical Chemistry 46, no. 3 (March 1, 2000): 313–18. http://dx.doi.org/10.1093/clinchem/46.3.313.
Full textAbstract:
Abstract Background: Expression of the hTERT gene, which codes for the catalytic subunit of telomerase, is associated with malignancy. We recently developed a real-time reverse transcription-PCR assay, based on TaqMan technology, for accurate and reproducible determination of hTERT mRNA expression (Lab Investig 1999;79:911–2). This method may be of interest for molecular tumor diagnostics in tissues and corresponding body fluids, washings, or brushes. Methods: In this study, we measured hTERT expression in a subset of healthy tissues and tumors to select those tumor types with the best potential for quantification of hTERT in corresponding body fluids. To demonstrate the use of the method in body fluids, we quantified hTERT expression in voided urine of patients with bladder cancer and controls. Results: Real-time measurement of hTERT expression could discriminate between all healthy and malignant tissue samples from pancreas, lung, esophagus, and bladder, but not for colon tissues. Moreover, in five of nine (55%) urine samples, hTERT could be quantified. Conclusions: The present study demonstrates that accurate quantitative measurement of hTERT expression has high potential for discrimination between healthy and tumor cells in tissues and urine and supports future measurements in pancreatic fluid, bronchoalveolar lavage fluid, esophageal brushings, and urine or bladder washings.
42
James, K., E. Eisenhauer, M. Christian, M. Terenziani, D. Vena, A. Muldal, and P. Therasse. "Measuring Response in Solid Tumors: Unidimensional Versus Bidimensional Measurement." JNCI Journal of the National Cancer Institute 91, no. 6 (March 17, 1999): 523–28. http://dx.doi.org/10.1093/jnci/91.6.523.
Full text
43
Morimoto, T., Y. Kinouchi, T. Iritani, S. Kimura, Y. Konishi, N. Mitsuyama, K. Komaki, and Y. Monden. "Measurement of the Electrical Bio-Impedance of Breast Tumors." European Surgical Research 22, no. 2 (1990): 86–92. http://dx.doi.org/10.1159/000129087.
Full text
44
Johnson, Aimee M., David L. Conover, Jiaoti Huang, Edward M. Messing, Ruola Ning, Mary J. O’Connell, M. Adrian Rossi, et al. "Early detection and measurement of urothelial tumors in mice." Urology 67, no. 6 (June 2006): 1309–14. http://dx.doi.org/10.1016/j.urology.2005.12.011.
Full text
45
Durduran, Turgut, Regine Choe, Guoqiang Yu, Chao Zhou, Julia C. Tchou, Brian J. Czerniecki, and Arjun G. Yodh. "Diffuse optical measurement of blood flow in breast tumors." Optics Letters 30, no. 21 (November 1, 2005): 2915. http://dx.doi.org/10.1364/ol.30.002915.
Full text
46
Miller, M. A., C. M. Mazewski, N. Yousuf, Y. Sheikh, L. M. White, G. A. Yanik, D. M. Hyams, B. C. Lampkin, and A. Raza. "Simultaneous immunohistochemical detection of IUdR and BrdU infused intravenously to cancer patients." Journal of Histochemistry & Cytochemistry 39, no. 4 (April 1991): 407–12. http://dx.doi.org/10.1177/39.4.2005370.
Full textAbstract:
Cell cycle kinetics of solid tumors in the past have been restricted to an in vitro labeling index (LI) measurement. Two thymidine analogues, bromodeoxyuridine (BrdU) and iododeoxyuridine (IUdR), can be used to label S-phase cells in vivo because they can be detected in situ by use of monoclonal antibodies (MAb) against BrdU (Br-3) or IUdR (3D9). Patients with a variety of solid tumors (lymphoma, brain, colon cancers) received sequential intravenous IUdR and BrdU. Tumor tissue removed at the end of infusion was embedded in plastic and treated with MAb Br-3 and 3D9 sequentially, using a modification of a previously described method. Clearly single and double labeled cells were visible, which enabled us to determine the duration of S-phase (Ts) and the total cell cycle time (Tc), in addition to the LI in these tumors. Detailed control experiments using tissue culture cell lines as well as bone marrow cells from leukemic patients are described, including the comparison of this double label technique with our previously described BrdU-tritiated thymidine technique. We conclude that the two methods are comparable and that the IUdR/BrdU method permits rapid and reliable cell cycle measurements in solid tumors.
47
Fergelot, P., N. Rioux-Leclercq, S. Zerrouki, K. Bensalah, and J. Patard. "Relationship between VHL mutation status, tumor VEGF expression and plasma VEGF measurement in sporadic renal cell carcinoma." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 4602. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4602.
Full textAbstract:
4602 Background: The relationship between VHL mutation status and prognosis in renal cell carcinoma (RCC) remains controversial. The aim of this study was to evaluate prospectively the association between VHL status, tumor VEGF expression, plasma VEGF levels and usual prognostic parameters in RCC. Methods: 70 patients with clear cell RCCs were included in this study. Genomic DNA was extracted using the QIAmp DNA mini kit (Qiagen) from frozen tumor samples. Four amplimers covering the whole coding sequence and exon/intron junctions of the VHL gene were synthetized by PCR followed by Big Dye sequencing (Applied Biosystems). Mutation bearing sequences were confirmed in a second round of PCR and sequencing reactions. Tumor VEGF expression was determined by immunohistochemistry and plasma VEGF was measured by enzyme-linked immunosorbent assay (Quantikine immunoassay, R&D systems). Results were expressed in pg/ml. Qualitative and quantitative variables were compared by using Chi-square (Fischer exact test) and Student t tests, respectively. Results: A VHL mutation was found in 46 cases (65.7%). VHL mutations were localized in exon 1, 2 and 3 in 23, 16 and 7 cases respectively. Median tumor VEGF expression was 45% (5–100). Median plasma VEGF was 104 pg/ml (13–1430). A significant association was found between VHL mutation and N stage (p: 0.01), Fuhrman grade, symptoms at presentation (p: 0.02) or tumor size (p: 0.007). A VHL mutation was found in 83.5% of low grade (G1–2) and 80% of incidental tumors respectively. A trend towards more frequent VHL mutations was observed in T1 tumors (87% mutation rate, p: 0.07) and in good performance status patients. Interestingly, VEGF tumor expression and plasma VEGF levels were not significantly different among patients with tumors having or not mutated VHL (p: 0.7). Conclusion: VHL mutations are more frequent in small incidental low stage or low grade tumors. Although VHL inactivation was not specifically determined in this study, we failed to show any association between VHL mutational status and VEGF tumor or plasma expression suggesting that other pathways than the VHL/HIF axis are required for explaining the angiogenic phenotype of RCC. No significant financial relationships to disclose.
48
Hirschberg, Henry, and Vidar Bosnes. "C-Reactive protein levels in the differential diagnosis of brain abscesses." Journal of Neurosurgery 67, no. 3 (September 1987): 358–60. http://dx.doi.org/10.3171/jns.1987.67.3.0358.
Full textAbstract:
✓ C-reactive protein (CRP) is a protein found in plasma at elevated concentrations during acute or chronic infections. As an aid in the differential diagnosis between brain tumor and abscess, the CRP levels were measured in 20 patients with intracranial mass lesions and the appearance of ring-like contrast enhancement on computerized tomography (CT) scans. In nine of these patients, the final diagnosis was abscess, based on either biopsy of the mass (eight patients) or the clinical course (one patient). In seven of the nine patients, there was a significant increase in CRP levels in two consecutive measurements. In particular, patients with cerebritis who were examined early in the course of the disease and who showed nonspecific CT scans exhibited extremely high levels of CRP. Two patients had no measurable CRP activity although they both had brain abscesses. In 12 patients harboring either gliomas or metastatic intracerebral tumors, CRP levels were significantly lower than those found in patients with brain abscesses but were nevertheless higher compared to those of a group of patients with benign tumors. It is concluded, therefore, that the measurement of CRP can have some value in the differential diagnosis between brain abscess and brain tumor. The measurement technique is inexpensive and is available in the clinical laboratories of most hospitals with a neurosurgical department.
49
Gazin, Aleksey A., Yury A. Vatnikov, and Ekaterina V. Abramova. "Morphological characteristics of testicular interstitial cell tumors in dogs." RUDN Journal of Agronomy and Animal Industries 17, no. 4 (December 27, 2022): 527–35. http://dx.doi.org/10.22363/2312-797x-2022-17-4-527-535.
Full textAbstract:
The study presents an assessment of variability of histological structure, measurement, and comparison of size of the neoplasm obtained by ultrasonographic examination and pathological examination, as well as the morphometric dimensions of nuclei and cytoplasm of testicular interstitial cell tumors in dogs. The study involved 35 dogs with neoplasms of 46 testes, where 11 animals had interstitial cell tumors in both testes. Insignificant differences of the size of these neoplasms were revealed (p 0.05) using ultrasonography and pathoanatomical measurement methods. Hence, it allows using both methods to assess the size of interstitial cell tumors. In the study, interstitial cell tumor was detected in both testes at once in 50 % of cases in dogs, however, this might be due to specific characteristics of the sample, and further research is required. In the course of scientific work, a morphological study showed the presence of variability in histological structure of interstitial cell tumors, which can lead to incorrect interpretation of the morphological picture and misdiagnosis, e. g. adipocyte-like morphology of interstitial cell tumors have morphological similarity to a benign neoplasm from adipose tissue - lipoma. In addition, there was an extremely pronounced difference in size of cytoplasm (from 23.6 to 148.4 m; average 66.21 22.42 m) and nuclei (from 9 to 57.6 m; average 23.19 7.10 m) in tumor cells. It proves the presence of pronounced anisocytosis and anisokariosis, which should indicate malignancy of the neoplasm, however, testicular interstitial cell tumors extremely rarely metastasize in practice and according to numerous studies.
50
Ferrari, Andrea, Rosalba Miceli, Cristina Meazza, Michela Casanova, Francesca Favini, Carlo Morosi, Giovanna Trecate, et al. "Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma." Journal of Clinical Oncology 28, no. 8 (March 10, 2010): 1322–28. http://dx.doi.org/10.1200/jco.2009.25.0803.
Full textAbstract:
Purpose In this study on a series of 205 patients with rhabdomyosarcoma, we investigated whether the prognostic effect of tumor size, at diagnosis or in terms of tumor response after induction chemotherapy, differed when tumor diameter or tumor volume were considered. Patients and Methods Tumor size was assessed radiologically at diagnosis and, for the 108 patients with measurable disease, after three courses of chemotherapy. The analysis was based on multivariable models (linear for association between size and patient/tumor characteristics, Cox for association with survival). The predictive performance of the Cox model (estimated by V measure) was compared for the tumor's diameter and volume. Results Initial tumor size was significantly larger in male or older patients and in T2 or alveolar tumors, but was not associated with the achievement of complete surgical resection. Initial tumor size significantly influenced overall survival. The risk of death was comparable for tumors 10 cm in maximum diameter and 194.0 cm3 in volume. The predictive performance of the Cox model was much the same when the tumor's diameter or volume was considered. Tumor response was a significant predictor of survival, again irrespective of the type of tumor measurement considered. Conclusion In our analysis, initial tumor size and tumor response were significant prognostic factors in rhabdomyosarcoma, regardless of whether tumor diameter or volume was considered. Three-dimensional tumor assessment was of no greater prognostic value than one-dimensional assessment, neither initially nor after induction treatment.